Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-05-07
Butterfly Network, Inc.
Butterfly Network sells semiconductor-based handheld ultrasound devices, cloud software, and workflow tools to clinicians, health systems, and commercial partners.
ai healthcare medical devices semiconductors software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Regulated handheld imaging with platform upside
The core device business looks real, and the upside comes from turning imaging IP into workflow and licensing revenue. The stock can work from here, but only if that higher-quality mix becomes repeatable over the next 18 months.

Analysis

Thesis
Butterfly is one of the few small-cap medtech names whose AI story is anchored in regulated hardware rather than a thin software wrapper; if iQ adoption keeps compounding and mix shifts toward workflow software and Embedded licensing, revenue can scale materially faster than the market still assumes.
Last Economy Alignment
Cheaper AI should expand who can scan and where scans happen, and Butterfly controls both the regulated probe and key workflow hooks. The upside is real, but healthcare regulation and incumbent bundling keep it below true AI infrastructure winners.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.6x (from 5 most recent analyses)
Reasoning
I only underwrite a durable rerating if Butterfly proves it is becoming a higher-quality mix business, not just shipping more probes. The path is continued iQ3 adoption, broader Embedded partner count, enterprise workflow adoption, and at least one real decentralized-care channel. If that happens, the business can earn a mid-single-digit revenue multiple by 2031; if not, it stays a premium device story without true platform valuation.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The key risk is not product viability; it is partial platformization. Butterfly already has a real handheld ultrasound product and a credible software layer, but the stock needs evidence that Embedded, workflow software, and decentralized-care channels become repeatable and diversified before incumbents bundle the category or regulators slow the roadmap.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.40
They control a regulated probe and a workflow layer that get more useful as AI helps more clinicians scan correctly in more settings. The upside is meaningful, but hospitals, regulators, and bigger imaging vendors can still slow how much of that value they keep.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$5.56
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case